ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1936

A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 2158

A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1822

A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1858

A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 2083

A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2168

A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1894

A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06)

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2008

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1899

A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1684

A Potent Inhibitor of PAD4 Suppresses Histone Citrullination in Vitro and in Vivo

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 1897

A Preliminary Estimate of Objectively Measured Sedentary Behavior in Knee Osteoarthritis

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 2082

A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1917

A Remote Behaviorally-Designed Intervention to Promote Physical Activity in Patients with Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1708

A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1777

A Symptom Checker App Is Better at Classifying Inflammatory Disease Than Physicians Who Are Presented Identical Information

Epidemiology and Public Health Poster III

«Previous Page
1
…
3
4
5
6
7
…
45
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].